Pair Name | Escin, Cisplatin | ||
Phytochemical Name | Escin (PubChem CID: 16211024 ) | ||
Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Escin, Cisplatin | |||
Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
Biological Phenomena | Induction-->Ferroptosis | |||
Gene Regulation | Down-regulation | Expression | G6PD | hsa2539 |
Down-regulation | Expression | GPX4 | hsa2879 | |
In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 | |
In Vivo Model | MDA-MB-231 cells (2.5×10⁶ cells per mouse) stably expressing sh-NC and sh-G6PD were established.When the tumor grew to approximately 60 mm3, 2 mg/kg Escin was intraperitoneally injected with normal saline as the control. | |||
Result | Role of Escin in breast cancer therapy: potential mechanism for inducing ferroptosis and synergistic antitumor activity with cisplatin |
No. | Title | Href |
---|---|---|
1 | Role of Escin in breast cancer therapy: potential mechanism for inducing ferroptosis and synergistic antitumor activity with cisplatin. Apoptosis. 2023 Aug;28(7-8):1154-1167. doi: 10.1007/s10495-023-01849-x. | Click |